David Mountcastle Sells 5,361 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,361 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $25.00, for a total transaction of $134,025.00. Following the transaction, the chief financial officer owned 172,909 shares in the company, valued at approximately $4,322,725. This trade represents a 3.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Mountcastle also recently made the following trade(s):

• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61.

Privia Health Group Price Performance

NASDAQ PRVA opened at $23.77 on Wednesday. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 139.82, a PEG ratio of 1.61 and a beta of 0.82. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51. The business’s fifty day moving average price is $23.07 and its 200-day moving average price is $23.54.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. Privia Health Group’s revenue was up 17.4% compared to the same quarter last year. Equities research analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Great Lakes Advisors LLC bought a new position in shares of Privia Health Group in the third quarter worth about $4,487,000. Advantage Alpha Capital Partners LP bought a new position in Privia Health Group in the 2nd quarter worth approximately $3,941,000. Hsbc Holdings PLC grew its holdings in Privia Health Group by 69.2% during the 2nd quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock valued at $2,549,000 after buying an additional 46,526 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in Privia Health Group during the 2nd quarter valued at approximately $2,209,000. Finally, Bailard Inc. bought a new stake in shares of Privia Health Group during the second quarter valued at approximately $531,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 results beat expectations — PRVA reported $0.25 EPS vs. $0.04 expected and revenue of $541.2M (up 17.4% YoY), a clear near‑term fundamental positive that supports higher valuations. Read More.
• Positive Sentiment: Truist raised its price target from $31 to $33 and kept a “buy” rating, which signals institutional confidence and can attract buyers. Read More.
• Positive Sentiment: Privia agreed to acquire Evolent’s ACO business to scale value‑based care — a strategic deal that could expand managed‑care revenue and improve margins if integration succeeds. Read More.
• Positive Sentiment: Privia‑led colorectal cancer screening program achieved an 84% screening rate, demonstrating execution in preventive care and EHR‑driven workflows — useful evidence for payor and provider partnerships. Read More.
• Neutral Sentiment: Citigroup trimmed its price target from $34 to $32 but maintained a “buy” rating — slightly dampening upside expectations while leaving the investment thesis intact. Read More.
• Negative Sentiment: Director Matthew Shawn Morris sold ~24,338 shares across Feb. 26–27 (~$608k), reducing his stake materially; heavy director sales can create short‑term selling pressure and hurt sentiment. Read More.
• Negative Sentiment: CFO David Mountcastle sold ~13,058 shares across Feb. 26–27 (~$327k); insider sales by senior finance executives are closely watched and may temper enthusiasm despite other positives. Read More.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Privia Health Group in a research note on Monday, December 29th. Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a research report on Friday, January 9th. They set an “outperform” rating and a $31.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. lifted their target price on Privia Health Group from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.